GJGuanming Jiang

Guanming Jiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guanming Jiang has a total of 72 co-authors. Here are the top co-authors by number of shared publications:

  • Jianqiang Liu

    Dongguan Key Laboratory of Drug Design and Formulation Technology, School of Pharmacy, Guangdong Medical University, Dongguan, 523808, China

    3 shared publications
  • Qinquan Tan

    Department of Thoracic Oncology, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People’s Hospital) , Dongguan, Guangdong, 523059

    2 shared publications
  • Sida Huang

    Dongguan Key Laboratory of Drug Design and Formulation Technology, Guangdong Provincial Key Laboratory of Research and Development of Natural Drugs, and School of Pharmacy, Guangdong Medical University, Guangdong Medical University Key Laboratory of Research and Development of New Medical Materials, Dongguan, 523808, China

    2 shared publications
  • Wan Zhang

    Department of Thoracic Oncology, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People’s Hospital) , Dongguan, Guangdong, 523059

    2 shared publications
  • Xiaojun Yang

    Department of Thoracic Oncology, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People’s Hospital) , Dongguan, Guangdong, 523059

    2 shared publications
  • Yihong Zeng

    Department of Thoracic Oncology, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People’s Hospital) , Dongguan, Guangdong, 523059

    2 shared publications

Latest Publications

  • Open Access

    Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study

    by Xiaojun Yang, Qinquan Tan, Shiyuan Chen, Jieyun Xie, Yihong Zeng, Ruinian Zheng, Qinglin Tan, Wan Zhang, Churen Yu, Ziying Hong, et al.

    Background: The standard first-line treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC) is EGFR tyrosine kinase inhibitors. However, concurrent mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma and combination therapies may offer a superior approach. This study explores the efficacy and safety of osimertinib plus anlotinib as first-line treatment for advanced NSCLC with EGFR co-mutations. Materials and Methods: This study prospectively enrolled patients with advanced NSCLC harboring EGFR (19Del/21L858R) mutations and ≥1 mutation in TP53, PIK3CA, or RB1, who had not undergone systemic treatment. Kaplan-Meier survival analysis tested the differences among patients with different concurrent mutations. ctDNA test was administered before and after treatment and its correlation with efficacy. Results: A total of 38 patients were enrolled, with co-mutations in TP53 (76.3%), PIK3CA (26.3%), and RB1 (2.6%). With a median follow-up of 25.6 months, the median progression-free survival (PFS) was 29.0 months (95% CI, 18.6-NR), and 1-year PFS rate was 85% (95% CI, 70.4%-94.5%). Objective response rate was 73.7% (95% CI, 56.9%-86.3%), and disease control rate was 100.0% (95% CI, 90.7%-100.0%). Adverse events of any grade occurred in all patients. Seven (18.4%) patients experienced grade 3 treatment-related adverse events (TRAEs), with no grade 4 TRAEs or treatment-related deaths. Conclusion: Osimertinib plus anlotinib shows promising efficacy and manageable toxicity as first-line treatment for advanced NSCLC with EGFR co-mutations (ChiCTR2300070023). Clinical trial registration: This study was registered in the Chinese Clinical Trial Registry (ChiCTR) under the registration number ChiCTR2300070023 on March 31, 2023 (https://www.chictr.org.cn).

  • Open Access

    EGFR tyrosine kinase inhibitors plus bevacizumab for advanced non-small cell lung cancer with concurrent alterations: A retrospective study

    by Ling Zhou, Xiaojun Yang, Xiumao Yin, Wan Zhang, Qinquan Tan, Yihong Zeng, Yanmin Cai, Haiji Yuan, Jia Chen, Weidong Liu, et al.

    Introduction: Patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and concurrent genetic alterations often face a poor prognosis and limited response to standard therapies. Objective: To evaluate and compare the efficacy and safety of EGFR tyrosine kinase inhibitors (EGFR-TKIs) in combination with bevacizumab versus EGFR-TKI monotherapy in patients with EGFR-mutant advanced NSCLC harboring concurrent genetic alterations. Methods: In this retrospective single-center study, clinical data from 52 patients treated between January 2017 and June 2021 were reviewed. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate, and safety. Results: Among the 52 patients included, the median PFS was 10.50 months in the combination group (n = 22) and 7.00 months in the monotherapy group (n = 30), with no statistically significant difference between groups (p = 0.099). The 6-month PFS rate was higher in the combination group (81.8% vs. 53.3%, p = 0.03). Exploratory subgroup analyses suggested improved PFS with combination therapy in patients with L858R mutations (p = 0.016) and TP53 co-mutations (p = 0.034), though the baseline L858R distribution was imbalanced between groups (p = 0.015). No statistically significant difference in OS was detected. Grade ≥3 adverse events were more frequent in the combination group (27.3% vs. 3.3%). Conclusion: EGFR-TKI plus bevacizumab did not significantly prolong PFS in the overall population compared to monotherapy. While potential benefits were observed in L858R and TP53 subgroups, the findings are constrained by the limited sample size and imbalances in baseline characteristics. The combination therapy showed increased but manageable toxicity. Larger, prospective studies are needed to validate these subgroup findings.

  • Advances and prospects of MIL-based drug delivery systems in the diagnosis and treatment of cervical cancer

    by Yize Zhang, Yanna Ye, Qiying Zhong, Zhiheng Yan, Ziyu Feng, Alireza Nezamzadeh-Ejhieh, Guangmin Jiang, Ying Pan, Zhanping Gou, Jian-Qiang Liu

    This review highlights the MIL-based nanoplatforms for chemotherapy (CT), chemodynamic therapy (CDT), photothermal therapy (PTT), photodynamic therapy (PDT), and related combination therapies in cervical cancer treatment.


  • Current status and prospects of MOFs loaded with H 2 O 2 -related substances for ferroptosis therapy

    by Yu Deng, Sida Huang, Guanming Jiang, Luyi Zhou, Alireza Nezamzadeh-Ejhieh, Jianqiang Liu, Zhikun Zhou

    Ferroptosis is a programmed cell death mechanism characterized by the accumulation of iron (Fe)-dependent lipid peroxides within cells. Ferroptosis holds excellent promise in tumor therapy. Metal–organic frameworks (MOFs) offer unique advantages in tumor ferroptosis treatment due to their high porosity, excellent stability, high biocompatibility, and targeting capabilities. Inducing ferroptosis in tumor cells primarily involves the production of reactive oxygen species (ROS), like hydroxyl radicals (˙OH), through iron-mediated Fenton reactions. However, the intrinsic H2O2 levels in tumor cells are often insufficient to sustain prolonged consumption, limiting therapeutic efficacy if ˙OH production is inadequate. Therefore, catalyzing or supplementing the intracellular H2O2 levels in tumor cells is essential for inducing ferroptosis by nanoscale metal–organic frameworks. This article reviews the biological characteristics and molecular mechanisms of ferroptosis, introduces H2O2-related substances, and reviews MOF-based nanoscale strategies for enhancing intracellular H2O2 levels in tumor cells. Finally, the challenges and prospects of this approach are discussed, aiming to provide insights into improving the effectiveness of ferroptosis induced by MOFs.


  • Open Access

    Advances in drug delivery-based therapeutic strategies for renal fibrosis treatment

    by Sida Huang, Hanqi Lu, Jin Chen, Chengyi Jiang, Guanmin Jiang, Govindhan Maduraiveeran, Ying Pan, Jianqiang Liu, Li-Er Deng

    Renal fibrosis is the result of all chronic kidney diseases and is becoming a major global health hazard.


  • HMGA1 promotes the development of esophageal squamous cell carcinoma by mediating miR-671-5p/lncRNA DLEU1

    by Pingping Lin, Qingshan Li, Xiying Lv, Jie Qu, Dongjuan Wang, Aike Li, Guanming Jiang

    Article: HMGA1 promotes the development of esophageal squamous cell carcinoma by mediating miR-671-5p/lncRNA DLEU1 - Panminerva Medica 2020 Jan 30 - Minerva Medica - Journals


  • Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand

    by Toufiq Ul Amin, Rasha Emara, Arindom Pal, Hala Aldawod, Guanming Jiang, Dengpan Liang, Tariqul Haque Tuhin, Abdulmalek Balgoname, Arjun D. Patel, Mamoun M. Alhamadsheh

    This work describes the enhancement of a novel antitumor therapeutic platform that combines advantages from small-molecule drug conjugates (SMDCs) and antibody drug conjugates (ADCs). Valine-citrulline (VCit) dipeptide linkers are commonly used cathepsin B cleavable linkers for ADCs. However, the instability of these linkers in mouse serum makes translating efficacy data from mouse to human more challenging. Replacing the VCit linker with glutamic acid-valine-citrulline (EVCit) has been reported to enhance the stability of ADCs in mouse serum. However, the effect of EVCit linker on the stability of SMDCs has not been reported. Here, we report that incorporating the EVCit linker in prostate-specific membrane antigen-targeting SMDCs, equipped with the transthyretin ligand AG10, resulted in conjugates with lower toxicity, an extended half-life, and superior therapeutic efficacy to docetaxel in a xenograft mouse model of prostate cancer. This should make SMDCs' preclinical toxicity and efficacy data from mice more reliable for predicting human results.


  • Open Access

    Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis

    by Xiaojun Yang, Yihong Zeng, Qinquan Tan, Zhihua Huang, Jun Jia, Guanming Jiang

    Immune checkpoint inhibitors (ICIs) are widely used to treat local or metastatic lung cancer. However, the efficacy of ICI in patients with brain metastases (BM) from lung cancer is unknown. This study aimed to evaluate the efficacy of PD-1/PD-L1 ICIs compared with chemotherapy for patients with lung cancer with BM. Electronic databases (PubMed, Embase, The Cochrane Library, and Web of Science) were searched. The meta-analysis assessed overall survival (OS) and progression-free survival (PFS) of the PD-1/PD-L1 inhibitors axis and its relationship with pathological type, drug modality, and the treatment line number in patients with BM from lung cancer. We included 694 patients with BM from lung cancer from 11 randomized controlled trials. Statistical analysis showed that compared with chemotherapy, PD-1/PD-L1 inhibitors could significantly prolong OS ( hazard   ratio   HR = 0.75 , 95 % confidence   interval   95 % CI = 0.51 – 0.99 ) and PFS ( HR = 0.65 , 95 % CI = 0.51 – 0.80 ). In the subgroup analysis, ICIs plus chemotherapy improved PFS ( HR = 0.60 , 95 % CI = 0.40 – 0.80 ), but not OS ( HR = 0.75 , 95 % CI = 0.30 – 1.19 ). The efficacy of ICI monotherapy in patients with BM was significantly different between OS and PFS: OS pooled HR = 0.81 ( 95 % CI = 0.57 – 1.05 ) and PFS = 0.78 ( 95 % CI = 0.62 – 0.94 ). Among different pathological types, the OS pooled HR was 0.67 (9 5 % CI = 0.39 – 0.95 ) for non-small cell lung cancer (NSCLC) and 0.94 ( 95 % CI = 0.56 – 1.33 ) for small cell lung cancer (SCLC); the PFS pooled HR was 0.58 ( 95 % CI = 0.39 – 0.76 ) for NSCLC and 0.79 ( 95 % CI = 0.65 – 0.93 ) for SCLC. Subgroups analysis of treatment line showed that no advantage for OS with ICIs as first-line or subsequent-line therapy, whereas ICIs as first-line ( HR = 0.63 , 95 % CI = 0.53 – 0.74 ) and second-line ( HR = 0.62 , 95 % CI = 0.62 – 0.96 ) benefitted PFS. This meta-analysis implied that compared with chemotherapy, PD-1/PD-L1 inhibitors significantly improved efficacy treatment of patients with BM from lung cancer. Further studies are needed to confirm the role of ICIs in different pathological types and drug treatment modalities.